Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥3,740.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥171.22B
Enterprise Value¥127.86B
Total Cash (Recent Filing)¥19.87B
Total Debt (Recent Filing)¥5.17B
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 14, 2026EPS Estimate
-61.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-112.69
Shares Outstanding65,817,420
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥30.28B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsTTM revenue growth of +76.5% combined with sustained ~74% gross margins indicate durable unit economics and expanding market traction. Strong top-line expansion with high gross margins supports long-term investment in R&D and commercial scale if operating leverage is restored.
Low Leverage / Capital FlexibilityVery low debt-to-equity (~0.10) and a large equity base provide financial flexibility to fund operations or absorb shocks without urgent refinancing. A conservative capital structure materially lowers short- to medium-term liquidity risk while cash generation recovers.
Proven Cash Generation HistoricallyPrior strong positive cash flow in 2023 shows the business can convert revenue to cash under improved operating conditions. That historical cash-generation ability implies a credible pathway back to self-funded growth once margins and working capital normalize.
Bears Say
Negative Operating & Free Cash FlowSustained negative operating and free cash flow (~-¥2.5B / -¥2.9B TTM) forces reliance on cash reserves or external financing, elevating execution and dilution risk. Continued cash deficits constrain reinvestment in commercialization and R&D over multiple quarters.
Weak Profitability & Operating LossesA negative TTM net margin (-8.5%) and recurring operating losses undermine retained earnings and the company’s ability to self-finance growth. Persistent underperformance in margins erodes long-term shareholder value unless structural cost or revenue improvements occur.
ROE Negative & Balance-sheet VolatilityNegative returns on equity and prior balance-sheet volatility (notably higher debt levels in 2024) signal unstable earnings and episodic leverage increases. This variability raises the risk profile and makes medium-term planning and capital allocation less predictable.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥3740.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥171.22B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 20 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on May 15, 2026. The company reported -¥38.2 earnings per share for the quarter, missing the consensus estimate of -¥2.74 by -¥35.46.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -61.64.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,817,420 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥38.2 in its last earnings report, missing expectations of -¥2.74. Following the earnings report the stock price went down -1.99%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)